148 related articles for article (PubMed ID: 20226872)
1. A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro.
Sabatini F; Petecchia L; Boero S; Silvestri M; Klar J; Tenor H; Beume R; Hatzelmann A; Rossi GA
Pulm Pharmacol Ther; 2010 Aug; 23(4):283-91. PubMed ID: 20226872
[TBL] [Abstract][Full Text] [Related]
2. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Tannheimer SL; Wright CD; Salmon M
Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
[TBL] [Abstract][Full Text] [Related]
3. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI
Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913
[TBL] [Abstract][Full Text] [Related]
4. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.
Buenestado A; Grassin-Delyle S; Guitard F; Naline E; Faisy C; Israël-Biet D; Sage E; Bellamy JF; Tenor H; Devillier P
Br J Pharmacol; 2012 Mar; 165(6):1877-1890. PubMed ID: 21913898
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
6. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.
Buenestado A; Chaumais MC; Grassin-Delyle S; Risse PA; Naline E; Longchampt E; Tenor H; Devillier P
PLoS One; 2013; 8(9):e74640. PubMed ID: 24066150
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.
Sanz MJ; Cortijo J; Taha MA; Cerdá-Nicolás M; Schatton E; Burgbacher B; Klar J; Tenor H; Schudt C; Issekutz AC; Hatzelmann A; Morcillo EJ
Br J Pharmacol; 2007 Oct; 152(4):481-92. PubMed ID: 17704822
[TBL] [Abstract][Full Text] [Related]
9. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
Izikki M; Raffestin B; Klar J; Hatzelmann A; Marx D; Tenor H; Zadigue P; Adnot S; Eddahibi S
J Pharmacol Exp Ther; 2009 Jul; 330(1):54-62. PubMed ID: 19386793
[TBL] [Abstract][Full Text] [Related]
10. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro.
Burgess JK; Oliver BG; Poniris MH; Ge Q; Boustany S; Cox N; Moir LM; Johnson PR; Black JL
J Allergy Clin Immunol; 2006 Sep; 118(3):649-57. PubMed ID: 16950284
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
Cortijo J; Iranzo A; Milara X; Mata M; Cerdá-Nicolás M; Ruiz-Saurí A; Tenor H; Hatzelmann A; Morcillo EJ
Br J Pharmacol; 2009 Feb; 156(3):534-44. PubMed ID: 19154443
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
14. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast N-Oxide in Combination with Formoterol Enhances the Antiinflammatory Effect of Dexamethasone in Airway Smooth Muscle Cells.
Patel BS; Rahman MM; Baehring G; Xenaki D; Tang FS; Oliver BG; Ammit AJ
Am J Respir Cell Mol Biol; 2017 Apr; 56(4):532-538. PubMed ID: 27997807
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of NOX4 expression by roflumilast N-oxide reduces markers of fibrosis in lung fibroblasts.
Vecchio D; Acquaviva A; Arezzini B; Tenor H; Martorana PA; Gardi C
Mediators Inflamm; 2013; 2013():745984. PubMed ID: 24027357
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
18. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
Timmer W; Leclerc V; Birraux G; Neuhäuser M; Hatzelmann A; Bethke T; Wurst W
J Clin Pharmacol; 2002 Mar; 42(3):297-303. PubMed ID: 11865966
[TBL] [Abstract][Full Text] [Related]
19. The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats.
Ding H; Zhang P; Li N; Liu Y; Wang P
Int Urol Nephrol; 2019 Feb; 51(2):253-260. PubMed ID: 30474782
[TBL] [Abstract][Full Text] [Related]
20. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
